| Bioactivity | Cimpuciclib is a selective CDK4 inhibitor (IC50: 0.49 nM) that has anti-tumor activity[1]. |
| Invitro | Cimpuciclib (example 63, 141.2 nM, 6 days) inhibits proliferation in colo205 cells[1]. Cell Proliferation Assay[1] Cell Line: |
| In Vivo | Cimpuciclib (example 63, 50 mg/kg, oral gavage, twice a week) inhibits tumor growth in colo205 tumor-bearing mice[1].Cimpuciclib (5 mg/kg for rats, 50 mg/kg for colo205 tumor-bearing mice, oral administration) shows slow metabolic rate and maintains high concentration in the plasma[1]. Animal Model: |
| Name | Cimpuciclib |
| CAS | 2202767-78-8 |
| Formula | C30H35FN8O |
| Molar Mass | 542.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Liu Shiqiang, et al. Preparation of benzimidazole compound as kinase inhibitor. Patent WO 2018045956. |